(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of -8.57% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.88%.
Biontech Se's revenue in 2026 is $3,011,363,636.On average, 24 Wall Street analysts forecast BNTX's revenue for 2026 to be $465,812,808,762, with the lowest BNTX revenue forecast at $409,672,502,820, and the highest BNTX revenue forecast at $580,622,263,256. On average, 22 Wall Street analysts forecast BNTX's revenue for 2027 to be $464,295,503,196, with the lowest BNTX revenue forecast at $286,517,867,713, and the highest BNTX revenue forecast at $613,244,332,925.
In 2028, BNTX is forecast to generate $608,692,416,227 in revenue, with the lowest revenue forecast at $272,609,233,358 and the highest revenue forecast at $792,792,158,235.